AGIR (Antibiotics against Resistant Infectious Germs)

The extraordinary diversity of life, which remains largely unexplored, holds a key to the discovery of new antimicrobial agents with innovative structures that should have the potential of overcoming antimicrobial resistances. DEINOVE launched the AGIR program to establish an integrated platform that would systematically explore the natural reservoir of bacterial metabolites, aiming to identify and develop novel antimicrobial candidates.

In 2017, the AGIR program was selected by the Investments for the Future Program and received financial support of €14.6m over 5 years for a total investment of €25m. This support materializes the commitment of the French public authorities in the fight against resistance to antimicrobial, a major health issue on a global scale.

Mobilizing and developing the tools to explore biodiversity

The AGIR program has implemented an innovative strategy for the discovery of new antimicrobials, both antibiotics and antifungals, through an integrated and automated approach. To date, the program has collected several thousands of bacterial strains from a number of diverse environmental niches, building a rich proprietary library of strains. Efforts are constantly mobilized to improve strain identification and cultivation strategies of rare and often uncultivated species. In parallel, screening assays to address the antimicrobial potential of these strains have been developed, as well as a strain and lead optimization platform that integrates automated genetic engineering, analytic strategies for compound purification and identification, and compound production.

With its expertise and platform, DEINOVE has already identified several strains of interest within its proprietary library, that display promising antimicrobial activities.

Extending the reach of the AGIR program through strategic partnerships

DEINOVE aims to maximize the opportunities to discover new antibiotic structures within its platform by expanding the search for natural compounds beyond its own bacterial library. To date, the Company has entered into partnerships with companies having portfolios of various strains collected as part of their pharmaceutical activities:

  • Naicons: An Italian biopharmaceutical company also specialized in the search for innovative antibiotics, NAICONS has a collection of 45 000 microbial strains. DEINOVE has access to a subset of carefully selected strains and will use the power of its automated discovery platform to detect and characterize antibiotic activities within them. If an activity was discovered in these strains, DEINOVE may acquire the strains either via a commercial license or full ownership, to initiate the development of drug candidates.
  • bioMérieux: Specialized in the field of infectious disease diagnosis, bioMérieux has one of the largest bacterial libraries in the world. As a first step, bioMérieux has given access to more than 250 strains belonging to 130 different species. DEINOVE and bioMérieux have jointly selected the strains for this project, aiming for a maximum of biological diversity.